Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pear Therapeutics, Inc. reported Full Year 2023 results: revenue $27 million to $37 million. Guidance initiated.
- Period
- Full Year 2023
- Revenue
- $27 million to $37 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Pear expects 2023 revenue in the range of $27 million to $37 million.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pear Therapeutics, Inc. reported Full Year 2022 results: revenue $14-16 million. Guidance reaffirmed.
- Period
- Full Year 2022
- Revenue
- $14-16 million
- Guidance
- reaffirmed
- Result
- guidance update
Exact text from the filing
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition. On November 14, 2022, Pear Therapeutics, Inc. (the "Company") issued a press release reporting the financial results of the Company for the third quarter ended September 30, 2022 and other
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.95
Pear Therapeutics, Inc. announced a restructuring with charges of approximately $2.6 million of cash based expenses related to employee severance, benefits, and related costs, and a stock-based compensation charge of between $ affecting workforce (approximately 59 employees).
- Type
- restructuring
- Charge
- approximately $2.6 million of cash based expenses related to employee severance, benefits, and related costs, and a stock-based compensation charge of between $
- Affected area
- workforce
- Headcount
- approximately 59 employees
Exact text from the filing
On November 14, 2022, due to the worsening macroeconomic environment, the Board of Directors of the Company approved a reduction in the Company's workforce by approximately 59 employees, representing approximately 22% of the Company's total workforce as of September 30, 2022. The reduction in workforce is intended to reduce operating expenses. In connection with the reduction in force, the Company estimates it will incur approximately $2.6 million of cash based expenses related to employee severance, benefits, and related costs, primarily in the fourth quarter of 2022, when it anticipates that the reduction in workforce will be substantially complete. In addition, the Company expects to record a stock-based compensation charge of between $0.3 million and $0.9 million and corresponding payroll tax expense related to modifications of equity awards for employees impacted by the reduction in workforce, subject to local law and consultation requirements, which could extend the process into
View on SEC.gov